Skip to main content

Melanotan I vs Melanotan II

Melanotan I and Melanotan II both have human research. The important differences are the preparation tested, the outcome measured and the depth of follow-up—not a simple mild-versus-strong ranking. This comparison separates clinical products, experimental findings and personal reports. For the wider context, see our tanning peptide guide.

By the Peptide Dossier Editorial TeamUpdated How we source

Melanotan I vs Melanotan II at a Glance

Melanotan 1 vs melanotan 2 comparison table
FactorMelanotan IMelanotan II
Structure[1] [2]Linear 13-amino-acid analogueCyclic seven-amino-acid analogue
Receptor target[1] [3]Predominantly MC1R bindingMultiple melanocortin receptors studied
FDA status[1] [6]Scenesse: adult EPP indicationUnapproved products cited in FDA enforcement
EMA status[5]Scenesse: EU authorization in 2014 for EPPNo corresponding approval established by sources reviewed
Approved form[1] [6]Scenesse implantNo approved formulation established here
PotencyNo validated cosmetic head-to-head conversionNo validated cosmetic head-to-head conversion
Nausea[1] [14]Reported in Scenesse trialsReported in small human studies
Appetite suppression[13]No comparative benefit established hereReduced appetite in a small ED trial
Erectile effects[14]Not established as ED therapy herePositive small controlled male studies
Human trial data[8] [9] [13]Early pigmentation studies and larger EPP trialsSmall pigmentation and ED trials exist
Adverse event monitoring[5] [10] [11]Scenesse product monitoring and EPP follow-upPublished trials and cases; limited long-term data
Cosmetic tanning use[8] [2]Pigmentation studied; distinct from licensed EPP usePilot pigmentation signal; no validated routine protocol

The table summarizes different evidence bases, not a head-to-head trial. A finding from a monitored study cannot automatically be transferred to a differently manufactured product, dose or purpose. Detailed study context and original sources follow below.

Mechanisms: Related Peptides, Distinct Questions

Afamelanotide is a 13-amino-acid alpha-MSH analogue with predominant MC1R binding and UV-independent eumelanin production. [1]

Melanotan II is a cyclic seven-amino-acid analogue. Its early human pilot demonstrated pigmentation and intermittent erections, showing why its effects cannot be described solely in terms of tanning. [2]

Laboratory researchers have examined Melanotan II and related cyclic analogues at human MC1, MC3, MC4 and MC5 receptors. Structural changes altered binding selectivity. Those experiments do not establish a clinical MT1-to-MT2 dose conversion or show that every adverse effect can be assigned to one receptor. [3]

Related melanocortin research includes bremelanotide (PT-141). Its approved product, Vyleesi, treats acquired, generalized HSDD in premenopausal women; it is not indicated for men, postmenopausal women or sexual-performance enhancement. A related molecule is not an interchangeable treatment. See the PT-141 vs Melanotan II comparison. [4]

Approval Status: Ingredient and Product Are Different

Scenesse is the US-approved afamelanotide implant for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP). That indication is not cosmetic tanning. [1]

The European Commission authorized Scenesse in December 2014 for prevention of phototoxicity in adults with EPP. Its authorization under exceptional circumstances includes additional monitoring; approval does not mean every question about long-term outcomes has been settled. [5]

FDA's 2020 Tailor Made warning letter identified compounded Melanotan II products among unapproved drugs that did not meet the cited 503A exemption conditions. Its current compounding safety record also flags Melanotan II. Neither a research-use label nor a seller's comparison with Scenesse establishes product approval. These records do not establish a blanket legal conclusion about every buyer or possession circumstance. See are peptides legal. [6] [7]

Research and approval answer different questions. Early trials can demonstrate a biological effect without establishing a marketed treatment. Conversely, approval of a particular formulation does not verify every product sold under the ingredient's other names.

Tanning and Light-Tolerance Evidence

A 1997 Melanotan I study tested intravenous, oral and subcutaneous administration in three male volunteers. Intravenous and subcutaneous treatment increased measured pigmentation; the effect remained three weeks after the ten-dose course. Occasional gastrointestinal upset and flushing were reported. This small exploratory study directly contradicts the idea that human tanning was never studied, but it is not a modern cosmetic regimen. [8]

Melanotan II's three-man phase-I pilot found increased pigmentation in two participants after five active doses over two weeks. This is a genuine positive human signal, with a very small sample. It cannot establish that MT2 tans everyone faster, at a reliably equivalent lower dose, or with a predictable fading schedule. [2]

Afamelanotide's larger controlled trials addressed EPP rather than ordinary cosmetic tanning. The published US trial reported median pain-free sunlight exposure of 69.4 hours versus 40.8 with placebo over six months; the separate European trial also favored treatment. Quality of life improved. Different recording windows prevent a simple comparison of the US and European hour totals. [9]

Personal accounts of faster or deeper tanning can be retained as experiences, but this review did not identify a controlled MT1-versus-MT2 cosmetic comparison supporting a universal potency or timing ranking. Product identity, skin characteristics and concurrent UV exposure would need to be measured, not assumed.

Adverse Effects and Longer-Term Follow-Up

Scenesse's pooled trials reported nausea in 19% versus 14% with vehicle. Serious hypersensitivity, including anaphylaxis, has been reported after marketing; prior severe hypersensitivity to its ingredients is a contraindication. [1]

A two-center observational series followed 115 EPP patients receiving 1,023 afamelanotide implants for up to eight years. Quality-of-life scores improved and remained higher; recorded treatment-attributed events were minor, chiefly nausea. Not every patient had eight years of follow-up, and this uncontrolled experience does not establish comparative safety against Melanotan II. [10]

Melanotan II's pilot recorded nausea, intermittent erections and, at the highest studied exposure in one participant, moderate fatigue and somnolence. The small trial cannot provide dependable population-wide frequency estimates. [2]

Serious case reports deserve context rather than an unsupported risk percentage. One chemically confirmed internet-sourced MT2 exposure was followed by systemic toxicity, muscle breakdown and kidney dysfunction. A separate report described renal infarction considered possibly related to MT2. These observations identify potential harms, not the rate at which they occur. [11] [12]

FDA also lists published reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxicity and priapism, alongside concerns about aggregation or peptide impurities in compounded preparations. That summary is not proof that every reported event was caused by MT2. Our peptide side effects guide explains evidence levels. [7]

Sexual Function: Small Controlled Studies Exist

In a ten-man placebo-controlled crossover study of psychogenic erectile dysfunction, eight men developed erections after Melanotan II. Nausea, yawning/stretching and decreased appetite occurred more often than with placebo, but none required treatment. This is acute experimental evidence in a defined male population, not proof of female libido benefits or a chronic treatment schedule. [13]

Another ten-man crossover study involving organic ED risk factors reported erections after 12 of 19 MT2 injections versus one of 21 placebo injections, with increased sexual desire. Severe nausea followed four of 19 MT2 injections. Injection counts must not be presented as participant response percentages. [14]

A later case report described acute ischemic priapism after MT2 injection requiring surgery when initial treatment failed. This is distinct from the transient erection measurements in trials. The favorable experimental signal and the serious case report both belong in the comparison; neither establishes a head-to-head treatment preference. See peptides for erectile dysfunction. [15]

Dosing, Preparation and Storage

Scenesse uses a 16 mg subcutaneous implant every two months, placed above the anterior supra-iliac crest by a trained healthcare professional. Refrigerate at 2–8°C and protect from light. [1]

Early injection studies tested pharmacology and short-term outcomes, not today's online loading and maintenance cycles. Their experimental schedules are not validated cosmetic regimens. [8] [2]

Unverified forum doses are not an established cosmetic protocol. A reported dose also does not establish a product's identity, concentration, stability or sterility. This comparison does not supply a reconstitution recipe or convert an implant regimen into instructions for a vial. See peptide storage and handling and research peptides explained.

Mole Changes, Cancer Questions and Monitoring

A case report described darkened and enlarging nevi in a teenage MT2 user who also used sunbeds and had familial melanoma risk. Another report described melanoma in situ associated with melanotan exposure. These reports warrant attention but cannot isolate a drug effect from background risk and other exposures or prove cancer causation. [16] [17]

Changing pigmentation should not be equated automatically with cancer—or dismissed automatically as an expected tan. The evidence reviewed here does not establish that melanotan prevents melanoma, nor that pigment changes make all clinical detection impossible. Those are stronger claims than the reports support.

Scenesse labeling recommends twice-yearly full-body skin examinations and continued light protection. [1]

The absence of a dedicated product-monitoring program is not the same as having no reporting pathway. FDA accepts voluntary suspected adverse-event and product-quality reports from clinicians and consumers. Such reports are signals for investigation, not controlled estimates of causality or frequency. [18]

Which Evidence Is Relevant to Your Question?

For EPP, randomized afamelanotide implant trials provide evidence of improved pain-free light exposure and quality of life. Those are meaningful disease-specific benefits, not merely a regulatory distinction. [9]

For cosmetic pigmentation, both molecules have early human findings, but the reviewed evidence does not establish a universally superior routine-use option. For sexual function, the relevant MT2 evidence is mainly small, acute male studies. These questions should remain separate rather than being collapsed into one winner.

Anecdotes can describe a person's experience and suggest worthwhile research questions. They become more useful when preparation, timing, other medicines, UV exposure and adverse effects are recorded. Popularity alone cannot establish how often a benefit or harm will occur.

Editorial Verdict

Afamelanotide has the more developed clinical evidence base for EPP. Melanotan II has real preliminary human pigmentation and erectile-response evidence—not an absence of trials. The reviewed studies do not justify a blanket cosmetic potency winner, dose equivalence or comparative safety ranking. Product identity and the intended outcome remain central.

Related reading: Tanning peptides: full guide, Melanotan II peptide profile, PT-141 vs Melanotan II, PT-141 (bremelanotide), GHK-Cu peptide, what are peptides, and peptide side effects.

Frequently Asked Questions About Melanotan

Afamelanotide has larger EPP trials and longer follow-up. That does not establish that an online MT1 vial is safer than MT2 or provide a head-to-head cosmetic risk estimate. Compare the actual preparation, population and follow-up, not just the molecule's name. [9, 10]

The premise is incorrect: nausea occurs with Scenesse too. MT2's small male studies documented both erections and nausea. [1, 13]

Afamelanotide is the molecule historically called Melanotan I. Scenesse is a particular implant product; the shared ingredient name does not demonstrate that a differently sourced vial has equivalent identity, manufacturing or clinical performance. [19]

Stronger needs an endpoint: receptor binding, pigmentation, erectile response and adverse effects are different measurements. The reviewed research does not establish a universal MT1-to-MT2 cosmetic dose conversion or a reliable faster-tanning winner. [3]

Cosmetic tanning is not Scenesse's licensed indication. Whether a particular off-label prescription is available and lawful is a separate clinical and legal question; an online listing is not evidence of that pathway. [5]

Afamelanotide can increase eumelanin without UV exposure. That does not establish equivalent photoprotection across products or justify adding sunbeds to deepen a tan. [1]

Product, intended use and jurisdiction matter. An authorized medicine and an online research product are not equivalent. The sources reviewed here do not establish a blanket answer about every purchase or possession situation.

Afamelanotide has the more developed evidence for EPP. MT2 nevertheless has controlled human pigmentation and erectile-function studies. Their small size and short observation periods limit conclusions about long-term cosmetic use. [9, 2, 13]

Sources

  1. Scenesse prescribing information
  2. Melanotan II phase-I pilot
  3. Cyclic analogue receptor-binding experiments
  4. Vyleesi prescribing information
  5. Scenesse European assessment
  6. FDA 2020 Tailor Made warning letter
  7. FDA compounding safety record
  8. Melanotan I human pigmentation study
  9. Afamelanotide randomized EPP trials
  10. Long-term observational EPP study
  11. MT2 systemic toxicity case
  12. Renal infarction case report
  13. MT2 psychogenic ED crossover trial
  14. MT2 organic ED crossover trial
  15. Ischemic priapism case report
  16. Nevus changes with MT2 and sunbeds
  17. Melanotan-associated melanoma in situ report
  18. FDA voluntary reporting information
  19. NCI afamelanotide identity record

Rankings reflect editorial judgment.